EGFRvIII

EGFRvIII 詳細

英語名Epidermal growth factor receptor variant III市販薬剤の数0
治験薬の数14ターゲットの別称
研究&開発段階Phase 2 Clinical
英語名Epidermal growth factor receptor variant III
ターゲットの別称
市販薬剤の数0
治験薬の数14
研究&開発段階Phase 2 Clinical

EGFRvIII 製品リスト

  • 属性

    Protein (9)Beads (1)

  • 製品ライブラリ

    オンライン (10)

  • 種

    Human (10)

  • タグ

    His Tag & Avi Tag (1)His Tag (7)- (1)Fc Tag (1)

  • マーカー

    Biotin-labeled (1)Unconjugated (2)FITC Labeled (1)- (1)PE Labeled (2)APC Labeled (2)AF488 Labeled (1)

EGFRvIIIバックグランド

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
WSD-0922WSD0922; WSD-0922Phase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma
詳細
Anti-EGFRvIII-CAREGFRvIII CAR; Anti-EGFRvIII-CARPhase 2 ClinicalKite Pharma, National Cancer InstituteBrain Neoplasms; Glioblastoma; Glioma; Gliosarcoma
詳細
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdColorectal Neoplasms
詳細
WSD-0922-FUWSD0922-FU; WSD-0922-FUPhase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours
詳細
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalNovartis Pharma Ag, University Of PennsylvaniaGlioblastoma
詳細
EGFRvIII-CARPhase 1 ClinicalDuke University Medical CenterGlioblastoma
詳細
Metabolically Armed EGFRvIII CAR-T cells therapy (Leman Biotech)Meta10-EGFRvIII; LMC005Phase 1 ClinicalLeman Biotech Co LtdGlioblastoma
詳細
APTN-101CBRX-101; APTN 101Phase 1 ClinicalAdaptin Bio IncGlioblastoma; Glioma
詳細
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)Phase 1 ClinicalCalifornia Institute For Regenerative Medicine, National Cancer InstituteGlioblastoma
詳細
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)DCTY0801; DCTY-0801Phase 1 ClinicalBeijing DCTY Biotech Co LtdGlioblastoma; Glioma
詳細
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co LtdGlioblastoma
詳細
RO-7428731RO-7428731; RG-6156Phase 1 ClinicalF. Hoffmann-La Roche LtdGlioblastoma
詳細
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdGlioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
詳細
89Zr-ABT806ClinicalHuashan HospitalGlioma
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報